These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 8693551

  • 41. Blockade of OX40 signals enhance survival of xenoislet grafts in spontaneously diabetic NOD mice.
    Honkanen-Scott M, Johnson J, Hering B, Bansal-Pakala P.
    Transplant Proc; 2008 Mar; 40(2):483-5. PubMed ID: 18374109
    [Abstract] [Full Text] [Related]

  • 42. Pancreatic islet xenograft tolerance after short-term costimulation blockade is associated with increased CD4+ T cell apoptosis but not immune deviation.
    Lehnert AM, Yi S, Burgess JS, O'Connell PJ.
    Transplantation; 2000 Mar 27; 69(6):1176-85. PubMed ID: 10762224
    [Abstract] [Full Text] [Related]

  • 43. Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis.
    Russell ME, Hancock WW, Akalin E, Wallace AF, Glysing-Jensen T, Willett TA, Sayegh MH.
    J Clin Invest; 1996 Feb 01; 97(3):833-8. PubMed ID: 8609241
    [Abstract] [Full Text] [Related]

  • 44. T-Cell co-stimulation by the CD28 ligand B7 is involved in the immune response leading to rejection of a spontaneously regressive tumor.
    Chaux P, Martin MS, Martin F.
    Int J Cancer; 1996 Apr 10; 66(2):244-8. PubMed ID: 8603819
    [Abstract] [Full Text] [Related]

  • 45. Expression and functional significance of an additional ligand for CTLA-4.
    Lenschow DJ, Su GH, Zuckerman LA, Nabavi N, Jellis CL, Gray GS, Miller J, Bluestone JA.
    Proc Natl Acad Sci U S A; 1993 Dec 01; 90(23):11054-8. PubMed ID: 7504292
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice.
    Freeman GJ, Borriello F, Hodes RJ, Reiser H, Hathcock KS, Laszlo G, McKnight AJ, Kim J, Du L, Lombard DB.
    Science; 1993 Nov 05; 262(5135):907-9. PubMed ID: 7694362
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Expression of CTLA4-Ig by biolistically transfected mouse islets promotes islet allograft survival.
    Gainer AL, Korbutt GS, Rajotte RV, Warnock GL, Elliott JF.
    Transplantation; 1997 Apr 15; 63(7):1017-21. PubMed ID: 9112357
    [Abstract] [Full Text] [Related]

  • 52. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation.
    Levisetti MG, Padrid PA, Szot GL, Mittal N, Meehan SM, Wardrip CL, Gray GS, Bruce DS, Thistlethwaite JR, Bluestone JA.
    J Immunol; 1997 Dec 01; 159(11):5187-91. PubMed ID: 9548454
    [Abstract] [Full Text] [Related]

  • 53. Blockade of CD40 pathway enhances the induction of immune tolerance by immature dendritic cells genetically modified to express cytotoxic T lymphocyte antigen 4 immunoglobulin.
    Sun W, Wang Q, Zhang L, Liu Y, Zhang M, Wang C, Wang J, Cao X.
    Transplantation; 2003 Nov 15; 76(9):1351-9. PubMed ID: 14627915
    [Abstract] [Full Text] [Related]

  • 54. Blockade of CD28/B7-2 costimulation inhibits experimental obliterative bronchiolitis in rat tracheal allografts: suppression of helper T cell type1-dominated immune response.
    Tikkanen JM, Lemström KB, Koskinen PK.
    Am J Respir Crit Care Med; 2002 Mar 01; 165(5):724-9. PubMed ID: 11874822
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Prevention of autoimmune recurrence and rejection by adenovirus-mediated CTLA4Ig gene transfer to the pancreatic graft in BB rat.
    Uchikoshi F, Yang ZD, Rostami S, Yokoi Y, Capocci P, Barker CF, Naji A.
    Diabetes; 1999 Mar 01; 48(3):652-7. PubMed ID: 10078573
    [Abstract] [Full Text] [Related]

  • 58. CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers.
    Wallace PM, Johnson JS, MacMaster JF, Kennedy KA, Gladstone P, Linsley PS.
    Transplantation; 1994 Sep 15; 58(5):602-10. PubMed ID: 8091487
    [Abstract] [Full Text] [Related]

  • 59. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection.
    Chandraker A, Azuma H, Nadeau K, Carpenter CB, Tilney NL, Hancock WW, Sayegh MH.
    J Clin Invest; 1998 Jun 01; 101(11):2309-18. PubMed ID: 9616202
    [Abstract] [Full Text] [Related]

  • 60. Feasibility of immunosuppression in composite tissue allografts by systemic administration of CTLA4Ig.
    Iwasaki N, Gohda T, Yoshioka C, Murakami M, Inobe M, Minami A, Uede T.
    Transplantation; 2002 Feb 15; 73(3):334-40. PubMed ID: 11884927
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.